In the present study, we aimed to confirm the previous finding of an association between GRIK4 and GNB3 variants (rs195478 and rs5443) and remission and treatment resistance in major depression, using a multicenter sample of 223 patients. We did not find any supporting evidence for such associations. These conflicting data may result from difficulties in the replication of candidate gene association studies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000329553 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmacogenomics in the treatment of mood disorders: Strategies and Opportunities for personalized psychiatry.
EPMA J
September 2017
Discipline of Psychiatry, School of Medicine, University of Adelaide, North Terrace, Adelaide, SA 5005 Australia.
Personalized medicine (personalized psychiatry in a specific setting) is a new model towards individualized care, in which knowledge from genomics and other omic pillars (microbiome, epigenomes, proteome, and metabolome) will be combined with clinical data to guide efforts to new drug development and targeted prescription of the existing treatment options. In this review, we summarize pharmacogenomic studies in mood disorders that may lay the foundation towards personalized psychiatry. In addition, we have discussed the possible strategies to integrate data from omic pillars as a future path to personalized psychiatry.
View Article and Find Full Text PDFPharmacogenetics and Imaging-Pharmacogenetics of Antidepressant Response: Towards Translational Strategies.
CNS Drugs
December 2016
Department of Psychiatry and Psychotherapy, Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany.
Genetic variation underlies both the response to antidepressant treatment and the occurrence of side effects. Over the past two decades, a number of pharmacogenetic variants, among these the SCL6A4, BDNF, FKBP5, GNB3, GRIK4, and ABCB1 genes, have come to the forefront in this regard. However, small effects sizes, mixed results in independent samples, and conflicting meta-analyses results led to inherent difficulties in the field of pharmacogenetics translating these findings into clinical practice.
View Article and Find Full Text PDFEuropean Group for the Study of Resistant Depression (GSRD)--where have we gone so far: review of clinical and genetic findings.
Eur Neuropsychopharmacol
July 2012
Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.
The primary objective of this review is to give an overview of the main findings of the European multicenter project "Patterns of Treatment Resistance and Switching Strategies in Affective Disorder", performed by the Group for the Study of Resistant Depression (GSRD). The aim was to study methodological issues, operational criteria, clinical characteristics, and genetic variables associated with treatment resistant depression (TRD), that is failure to reach response after at least two consecutive adequate antidepressant trials. The primary findings of clinical variables associated with treatment resistance include comorbid anxiety disorders as well as non-response to the first antidepressant received lifetime.
View Article and Find Full Text PDFFailure to replicate influence of GRIK4 and GNB3 polymorphisms on treatment outcome in major depression.
Neuropsychobiology
June 2012
Institute of Psychiatry, University of Bologna, Bologna, Italy. alessandro.serretti @ unibo.it
In the present study, we aimed to confirm the previous finding of an association between GRIK4 and GNB3 variants (rs195478 and rs5443) and remission and treatment resistance in major depression, using a multicenter sample of 223 patients. We did not find any supporting evidence for such associations. These conflicting data may result from difficulties in the replication of candidate gene association studies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!